Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven A Smith

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
Bioorganic & Medicinal Chemistry Letters|December 19, 2008
CB2 selective sulfamoyl benzamides: optimization of the amide functionalityAllan J Goodman, Christopher W Ajello, Karin Worm, et al.
Bioorganic & Medicinal Chemistry Letters|November 19, 2009
Novel sulfamoyl benzamides as selective CB(2) agonists with improved in vitro metabolic stabilityIan Sellitto, Bertrand Le Bourdonnec, Karin Worm, et al.
Endocrine|September 9, 2021
Making sense of diabetes medication decisions: a mixed methods cluster randomized trial using a conversation aid interventionMarleen Kunneman, Megan E Branda, Jennifer L Ridgeway, et al.
Journal of Medicinal Chemistry|September 16, 2008
Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859)Bertrand Le Bourdonnec, Rolf T Windh, Christopher W Ajello, et al.
Journal of Medicinal Chemistry|August 22, 2009
Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5747)Bertrand Le Bourdonnec, Rolf T Windh, Lara K Leister, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
Bioorganic & Medicinal Chemistry Letters|December 19, 2008
CB2 selective sulfamoyl benzamides: optimization of the amide functionalityAllan J Goodman, Christopher W Ajello, Karin Worm, et al.
Bioorganic & Medicinal Chemistry Letters|November 19, 2009
Novel sulfamoyl benzamides as selective CB(2) agonists with improved in vitro metabolic stabilityIan Sellitto, Bertrand Le Bourdonnec, Karin Worm, et al.
Endocrine|September 9, 2021
Making sense of diabetes medication decisions: a mixed methods cluster randomized trial using a conversation aid interventionMarleen Kunneman, Megan E Branda, Jennifer L Ridgeway, et al.
Journal of Medicinal Chemistry|September 16, 2008
Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859)Bertrand Le Bourdonnec, Rolf T Windh, Christopher W Ajello, et al.
Journal of Medicinal Chemistry|August 22, 2009
Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5747)Bertrand Le Bourdonnec, Rolf T Windh, Lara K Leister, et al.
Pageof 7